ืคื™ืœื˜ืจื™ื

โ‚ช
ืœ
โ‚ช
43 ืžื•ืฆืจื™ื
ืžื™ื™ืŸ ืข"ื™
ืžื™ื™ืŸ ืข"ื™
ืืงืกื˜ืจื ืฉื™ืฉื™ื™ืช ื›ืจื™ื•ืช ื™ืคื ื™ื•ืช ืžื”ื“ื•ืจืช ืงื™ืฅ-pharm2u ืืงืกื˜ืจื ืฉื™ืฉื™ื™ืช ื›ืจื™ื•ืช ื™ืคื ื™ื•ืช ืžื”ื“ื•ืจืช ืงื™ืฅ-pharm2u
ืืงืกื˜ืจื ืฉื™ืฉื™ื™ืช ื›ืจื™ื•ืช ื™ืคื ื™ื•ืช ืขื‘ื•ืช ืคืจื™ืžื™ื•ื-pharm2u ืืงืกื˜ืจื ืฉื™ืฉื™ื™ืช ื›ืจื™ื•ืช ื™ืคื ื™ื•ืช ืขื‘ื•ืช ืคืจื™ืžื™ื•ื-pharm2u
ื›ืคืคื•ืช ืจื‘ ืคืขืžื™ื•ืช ืืงืกื˜ืจื  S ืžื™ื“ื”-pharm2u ื›ืคืคื•ืช ืจื‘ ืคืขืžื™ื•ืช ืืงืกื˜ืจื  S ืžื™ื“ื”-pharm2u

ืฉื™ืจื•ืช ืžืฉืœื•ื—ื™ื ืื™ื›ื•ืชื™ ื•ืžื”ื™ืจ

ืœื‘ื—ื™ืจืชื›ื: ืžืฉืœื•ื— ืขื ืฉืœื™ื— ืขื“ ื”ื‘ื™ืช ,ืžืฉืœื•ื— ืœื ืงื•ื“ืช ืื™ืกื•ืฃ ืื• ืื™ืกื•ืฃ ืขืฆืžื™. ืžืขืœ 399 ืฉ"ื—, ื”ืžืฉืœื•ื— ืœื ืง' ืื™ืกื•ืฃ ื—ื™ื ื